Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC)

被引：9
|
作者：
Szczylik, C.
Porta, C.
Bracarda, S.
Hawkins, R.
Bjarnason, G. A.
Oudard, S.
Lee, S.
Carteni, G.
Hariharan, S.
Gore, M. E.
机构：
[1] Mil Med Inst, Warsaw, Poland
[2] IRCCS San Matteo Univ Hosp Fdn, Pavia, Italy
[3] Azienda Osped Perugia, Perugia, Italy
[4] Christie Hosp, Manchester, Lancs, England
[5] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[6] Hop Europeen Georges Pompidou, Paris, France
[7] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[8] Pfizer Inc, New York, NY USA
[9] Royal Marsden Hosp NHS Trust, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5124
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5124
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Predictive biomarkers in metastatic Renal Cell Carcinoma (mRCC) patients treated with neoadjuvant sunitinib (PREINSUT trial)
    Mauge, L.
    Pereira, H.
    Gille, A. S.
    Bouaboula, M.
    Grine, A.
    Elaidi, R. T.
    Tartour, E.
    Fournier, L.
    Oudard, S.
    Helley, D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S34 - S34
  • [22] SAFETY PROFILE OF SUNITINIB AND SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Massari, Francesco
    Sperandi, Francesca
    Cricca, Antonia
    Melotti, Barbara
    Martoni, Andrea Angelo
    ANNALS OF ONCOLOGY, 2009, 20
  • [23] CARDIOTOXICITY IN METASTATIC RENAL CELL CARCINOMA (mRCC) PATIENTS TREATED WITH SUNITINIB (SU)
    Ballatore, Valentina
    Prati, Veronica
    Ruatta, Fiorella
    Galizia, Danilo
    Grignani, Giovanni
    Aglietta, Massimo
    Ortega, Cinzia
    ANTICANCER RESEARCH, 2012, 32 (05) : 1876 - 1877
  • [24] Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Feldman, D. R.
    Kondagunta, G. V.
    Ronnen, E. A.
    Fischer, P.
    Chang, R.
    Baum, M.
    Ginsberg, M. S.
    Ishill, N.
    Patil, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma
    Barrios, Carlos H.
    Herchenhorn, Daniel
    Chacon, Matias
    Cabrera-Galeana, Paula
    Sajben, Peter
    Zhang, Ke
    ONCOTARGETS AND THERAPY, 2016, 9 : 5839 - 5845
  • [26] Pharmacokinetics (PK) and efficacy of sunitinib in patients with metastatic renal cell carcinoma (mRCC).
    Houk, B. E.
    Amantea, M.
    Motzer, R. J.
    Michaelson, M. D.
    Rini, B. I.
    George, D. J.
    Redman, B. G.
    Hudes, G. R.
    Poland, B.
    Bello, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 224S - 224S
  • [27] Sunitinib in patients with cytokine-refiractory metastatic renal cell carcinoma (mRCC)
    George, D. J.
    Michaelson, M. D.
    Rosenberg, J. E.
    Redman, B. G.
    Hudes, G. R.
    Bukowski, R. M.
    Kim, S. T.
    Chen, I.
    Wilding, G.
    Motzer, R. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 304 - 304
  • [28] EXPANDED-ACCESS PROGRAM (EAP) OF SUNITINIB IN 458 PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Sternberg, C. N.
    Porta, C.
    Bracarda, S.
    Carteni, G.
    Lo Re, G.
    Ruggeri, E. M.
    Conte, P.
    Monfardini, S.
    Gasparini, G.
    Ciuffreda, L.
    ANNALS OF ONCOLOGY, 2008, 19 : 194 - 194
  • [29] Subpopulation analysis from an ongoing expanded-access trial of Sunitinib in metastatic renal cell carcinoma
    Eberhardt, W.
    Weigang-Koehler, K.
    Gruenwald, V.
    Fiedler, W.
    Steiner, T.
    Stoeckle, M.
    Bergmann, L.
    Casper, J.
    Wirth, M. P.
    Gore, M. E.
    ONKOLOGIE, 2008, 31 : 179 - 179
  • [30] Sunitinib in Clinical Practice: the Expanded Access Program for Metastatic Renal Cell Carcinoma
    Marschner, Norbert
    ONKOLOGIE, 2010, 33 : 12 - 14
12345